Access cutting-edge alzheimer's disease treatment through this clinical trial at a research site in Denver. Study-provided care at no cost to qualified participants.
Access alzheimer's disease specialists in Denver at no cost
This study follows strict safety protocols and ethical guidelines
All study-related alzheimer's disease treatment provided free
Xanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD). This XanaMIA Phase 2b/3 study is to investigate the safety, tolerability, and efficacy of Xanamem in in mild or moderate dementia due to AD. Trial participants will be randomized to either receive 10mg of Xanamem once daily or a placebo for 36 weeks at a 1:1 ratio in a double-blinded fashion.
Sponsor: Actinogen Medical
Check if you qualify for this alzheimer's disease clinical trial in Denver, CO
If you're searching for alzheimer's disease treatment options in Denver, CO, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Denver research site is actively enrolling participants for this clinical trial. You'll receive care from experienced alzheimer's disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.